Find the latest science, technology and partners in antibody engineering, immunobiology and next generation binders.

Emerging technologies in antibody engineering and therapeutics

Monoclonal antibodies are expected to make up just under half of the USD $22.7 billion biologics discovery market by 2025. With this comes great technological innovation and novel approaches to antibody engineering and therapeutics. This whitepaper discusses the latest strategies and challenges, looking at:

- Automation
- Immune repertoire analysis
- Next Generation Sequencing and Bioinformatics
- Display technology and antibody characteristics
- Bispecific Antibodies
- The Challenges of mAbs
- Next generations “antibody-like” protein therapeutics


To download the exclusive whitepaper simply log in or register for an Informa Connect account, which will give you access to all our exclusive premium content.

Have any questions about the whitepaper or interested in sponsoring a future whitepaper? Email andrew.burrows@informa.com.

This piece represents the views of the author and not necessarily the views of Informa Connect Life Sciences or the Antibody Therapeutics and Engineering conference series.

Create your Informa Connect account

Access this and more industry news, views, and keynotes from influencers and market movers.
Show
Please tick these boxes if you do not wish to receive marketing information relevant to you from Informa Connect:
By creating an account you agree to Informa's Terms of Use and Privacy Policy